|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12Q 1/68 |
| (11) | Number of the document | 2820151 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13707527.1 |
| Date of filing the European patent application | 2013-02-22 | |
| (97) | Date of publication of the European application | 2015-01-07 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2013/027441 |
| Date | 2013-02-22 |
| (87) | Number | WO 2013/130364 |
| Date | 2013-09-06 |
| (30) | Number | Date | Country code |
| 201261604290 P | 2012-02-28 | US |
| (72) |
CONG, Feng, US
HAO, Huaixiang, US
HSIEH, Hsin-i, US
JIANG, Xiaomo, US
LIU, Jun, US
NG, Nicholas, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |
| CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |